Who invested in 858 Therapeutics?
858 Therapeutics's investors include New Enterprise Associates, Insight Partners, Versant Ventures, Cormorant Asset Management and Alexandria Venture Investments.

United States · Series B startup
One round we have observed, with the 5 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Follow 858 Therapeutics and see its new rounds in your feed.Sign up free
Funding summaryUpdated 27 Oct 2026
$50Mraised across 1 round since 2024, from 1 source
Source recordedSEC filing: $25M sold, first sale Jun 2024
From 858 Therapeutics's own website: 2 on the team.
858 Therapeutics's investors include New Enterprise Associates, Insight Partners, Versant Ventures, Cormorant Asset Management and Alexandria Venture Investments.
858 Therapeutics has raised $50M across 1 round since 2024.
858 Therapeutics's most recent round was a Series B of $50M in Sept 2024.
Its most recent round, $50M in Sept 2024, is also its largest on record.
858 Therapeutics's first round on record, in Sept 2024, was backed by New Enterprise Associates, Insight Partners and Versant Ventures and 2 others.
858 Therapeutics's latest named round is a Series B, in Sept 2024.
858 Therapeutics is based in the United States.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.